A study confirmed that Ras and RhoA are the targets of sevoflurane in the treatment of cervical cancer and found that sevoflurane can inhibit the downstream signaling pathways Ras/Erk/Akt and Rho/MYPT1/MLC of both targets. This evidence concerns the gene RHOA and cervical carcinoma.